Company News
Soaring into the Future, Winning Together — 2019 Dealer Conference & E6E7 New Product Launch Successfully Held
On May 25, 2019, the Boai Xinkaiyuan Group Wuhan Heer Medical 2019 Dealer Conference and E6E7 New Product Launch was held at the Wuhan High-Speed Rail Carre International Hotel. Group Vice Chairman Wang Jianqiang and other senior leaders attended, with the launch of HPV-E6E7 protein detection technology and the "Lingyun" AI cervical cancer screening system.
On May 25, 2019, on a bright and sunny spring day, the Boai Xinkaiyuan Group Wuhan Heer Medical 2019 Dealer Conference and E6E7 New Product Launch officially opened at the Wuhan High-Speed Rail Carre International Hotel.
Xinkaiyuan Group's leadership expressed strong support and high regard for this conference. Vice Chairman Wang Jianqiang, Group Vice President Zhang Junzheng, and Group Vice President Liu Dan attended the event in person.
Boai Xinkaiyuan Group Vice Chairman Wang Jianqiang and Wuhan Heer Medical Founder Ren Dalong each delivered opening remarks, extending a warm welcome to all attending dealers.
Mr. Wang Jianqiang, Vice Chairman of Boai Xinkaiyuan Group
Mr. Ren Dalong, Founder of Heer Medical and Group Vice President
The conference focused on the launch of Heer Medical's latest products: HPV-E6E7 Protein Detection Technology, next-generation molecular screening for breast cancer, and Xinkaiyuan biomedical product recommendations. Heer Medical introduced patent antibodies from Stanford University in the United States and, using immunohistochemical methods targeting HPV-E6E7 protein — the direct carcinogen of HPV-induced cervical cancer — has innovatively developed a highly specific HPV-E6E7 protein detection technology for cervical cancer. The launch of these new products attracted intense interest and lively discussion from all attendees.
Company technicians demonstrated instrument operation and provided detailed product explanations to every attendee
The conference also showcased the newly developed "Lingyun" series AI Cervical Cancer Screening and Analysis System — a single instrument delivering multiple functions: DNA quantitative analysis, remote consultation, 24-slide automatic loading and unloading, combined DNA ploidy + E6E7 protein analysis, and HPV-E6E7 protein analysis. Attendees then visited Heer Medical's company premises, main production areas, production workshop, and Heer Medical Laboratory.
"The road ahead is long and hard as iron — let us march forward anew." Let us move forward together, side by side, with great ambition and resolve, setting sail for our dreams and striving for a better life!
Group photo of all attendees at the 2019 Xinkaiyuan Group Wuhan Heer Medical Dealer Conference